Boehringer Ingelheim and Xencor enter a collaboration agreement
21 February 2012 | By Boehringer Ingelheim
Antibodies engineered with Xencor’s proprietary Xtend™ technology for increasing antibody half-life...
List view / Grid view
21 February 2012 | By Boehringer Ingelheim
Antibodies engineered with Xencor’s proprietary Xtend™ technology for increasing antibody half-life...
3 February 2012 | By Boehringer Ingelheim
Research collaboration agreement to develop new insights into the causes of diabetes...
30 January 2012 | By Eli Lilly and Company
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto™ (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin. JENTADUETO provides a new, single-tablet treatment option, taken twice-daily, for patients who…
26 January 2012 | By Boehringer Ingelheim
Boehringer Ingelheim announced the initiation of two phase III clinical trials...
26 January 2012 | By Boehringer Ingelheim
Boehringer Ingelheim has expanded its biopharmaceutical cell line development services...
14 December 2011 | By Boehringer Ingelheim
Boehringer Ingelheim announced that the company intends to invest 70 million Euro to expand its manufacturing plant in the Zhangjiang High-Tech Park in Shanghai...
9 December 2011 | By Boehringer Ingelheim
The final patient has been randomised to treatment in the large-scale Phase III clinical trial programme for BI 201335...
1 December 2011 | By Boehringer Ingelheim
AVEO & Boehringer Ingelheim enter into an agreement...
27 October 2011 | By Boehringer Ingelheim
Update across Europe on Pradaxa®...
5 October 2011 | By Gilead Sciences
Gilead Sciences, Inc. and Boehringer Ingelheim have entered into a licensing agreement...
27 September 2011 | By Boehringer Ingelheim
Results from a Phase I/II study...
26 September 2011 | By Boehringer Ingelheim
Boehringer Ingelheim will establish a new separate business for the development and commercialization of own biosimilars...
22 September 2011 | By Boehringer Ingelheim
Phase II clinical trial results...
21 September 2011 | By Boehringer Ingelheim
Once-daily Viramune® (nevirapine) prolonged-release has received approval...
7 September 2011 | By Boehringer Ingelheim
Boehringer Ingelheim wins the '2011 European Bio Pharmaceutical Contract Manufacturing Competitive Strategy Leadership Award'...